Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REVERSE-AD Phase III study of idarucizumab for reversal of dabigatran anticoagulation
2013-004813-41Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Feb 2014
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of idarucizumab in Bleeding and cardiac morbidity (2 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Reversal of anticoagulant effect of dabigatran. Started Feb 2014; status: completed.
02
Drugs
idarucizumab
03
Conditions
Bleedingcardiac morbidity
Beyond the preview
Go deeper on 2013-004813-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004813-41.